- Academic Editor
-
-
-
†These authors contributed equally.
Background: To investigate the diagnostic value of SMARCE1,
cysteine-rich secreted protein 3 (CRISP3) combined with tumor markers in the
diagnosis of cervical cancer. Methods: A total of 80 patients with
cervical lesions who were diagnosed and treated in our hospital from January 2020
to March 2022 were selected and divided into control group (chronic cervicitis, n
= 30) and observation group (cervical cancer, n = 50). Immunohistochemistry was
used to detect the expression levels of SMARCE1 and CRISP3 in cervical
tissue of the two groups of subjects, and the relationship between the expression
of SMARCE1 and CRISP3 in cervical cancer tissue and the
clinicopathological data of the patients was analyzed. In addition, the serum
tumor marker levels of the two groups of subjects were detected, and the
diagnostic value of SMARCE1 and CRISP3 combined with tumor markers in
cervical cancer was analyzed. The female sexual function index (FSFI) and the
functional assessment of cancer therapy-general (FACT-G) score were used to
evaluate female sexual function and quality of life. Results: The
positive expression rates of SMARCE1 and CRISP3 in the observation group
were significantly higher than those in the control group (p